In Vivo Infographics
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Snapshot: July Highlights
A selection of articles you might have missed from July 2022, including an exploration of this year's top selling drugs, an in depth discussion about how life sciences leadership is changing, as well as a look into AC Immune's Parkinson's research.
Challenging Alzheimer's: Korean Firms Forge Ahead In Multiple Modalities
In Vivo takes an infographic look at where South Korea stands in the development of a wide-ranging set of drugs for Alzheimer’s disease and which companies are still in the challenging race.
Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.
Snapshot: June Highlights
A selection of articles you might have missed from June 2022, including a deep dive into venture finance, an in depth discussion about Russia's upcoming drug supply woes, and the latest Rising Leaders interviews.
Snapshot: April Highlights
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.
In Vivo's 2022 Rising Leaders At A Glance
Top 30 Leaders: see the list of entrepreneurs and innovators highlighted in the third edition of In Vivo's Rising Leaders series.
Snapshot: March Highlights
A selection of articles you might have missed from March 2022, including exclusive interviews and an in-depth look at the targeted protein degradation field.
Bugs As Drugs: The Budding Microbiome Modulator Pipeline
INFOGRAPHIC: The sheer number of micro-organisms in the human body and their functions makes the microbiome a ripe target for therapeutic intervention. While still rather early, data show the microbiome modulator pipeline has immense potential across a range of therapeutic areas, not just in gastrointestinal disease.
2021 Deal-Making Snapshot
M&A deals valued at $10bn or more were scarce in 2021, as the industry focused on easier-to-integrate bolt-ons. Alliance activity increased, but the average value on licensing and partnership deals was lower than in 2020.
Infographic: 2021 Top Big Pharma Deal-Makers
Roche/Genentech was the busiest deal-maker in big pharma for second consecutive year in 2021, followed by Sanofi, Takeda, Lilly, Novartis and Pfizer.
Snapshot: January Highlights
A selection of articles you might have missed from January 2022, including exclusive interviews and a look at the oncology microbiome pipeline.
When It Comes To Sponsor Meetings, FDA Is Getting A ‘D’
New ‘Type D’ meetings will be added as part of PDUFA VII, one of a spate of changes under the next version of the user fee program that will begin in October 2022.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.